Nabsys Electronic Genome Mapping Advances Cancer Analysis
Providence, Rhode Island, USA, September 17, 2026 Nabsys, Inc. has announced the publication of research from Augusta University demonstrating...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Providence, Rhode Island, USA, September 17, 2026 Nabsys, Inc. has announced the publication of research from Augusta University demonstrating...
NATICK, MASSACHUSETTS, AND RENO, NEVADA, Aug 27, 2026 Pillar Biosciences, Inc. and Hamilton Company have announced the validation and...
CAMBRIDGE, United Kingdom, July 6, 2026 Astex Pharmaceuticals has entered into an exclusive worldwide research collaboration and license agreement...
TAMPA, Fla., June 15, 2026 TuHURA Biosciences, Inc. has announced the filing of an Investigational New Drug (IND) application...
WARSAW, Poland, June 3, 2026 Ingenix, an emerging artificial intelligence company focused on transforming drug discovery through advanced biological...
NEWTON, Mass., June 1, 2026 Karyopharm Therapeutics has announced that it will host an investor conference call featuring leading...
COLUMBUS, Ohio and CHICAGO, June 1, 2026 Paradigm Health has announced the successful implementation of its SPIRE (Scalable Platform...
IRVINE, California, May 29, 2026 PeproMene Bio, Inc. has announced that updated clinical data from its ongoing Phase 1...
AUSTIN, Texas | May 2026 Natera, Inc. announced a new collaboration with Diakonos Oncology Corp. to utilize its personalized...
CHENGDU, China, May 29, 2026 Kelun-Biotech has presented pivotal Phase II clinical trial results for its next-generation selective RET...
